Levosimendan and postoperative NT-proBNP release in noncardiac surgery – a prospective, randomized, double-blinded, phase III trial
Preprint
- 12 December 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Postoperative elevated NT-proBNP concentrations are independently associated with cardiovascular complications and mortality after noncardiac surgery. Levosimendan significantly decreases the release of NT-proBNP, however, the effect in noncardiac surgical patients remains unknown. Thus, this study evaluates the effect of a perioperative levosimendan administration on postoperative maximum NT-proBNP. Methods: 230 cardiovascular risk patients undergoing moderate- to high-risk major noncardiac surgery were included in this prospective, double-blinded, parallel group, placebo-controlled, phase III trial, between October 2020 through November 2023. 115 patients were assigned to perioperative single-dose of 12.5mg starting with a rate of 0.2 mcg.kg-1.min-1 of levosimendan and 115 patients were assigned to placebo. The primary outcome was postoperative maximum NT-proBNP concentration within the first three postoperative days. Secondary outcomes were MINS and maximum troponin T concentrations within the first three postoperative days. Results: Among 230 patients, 228 patients completed the trial. There was no significant difference in postoperative maximum NT-proBNP concentrations between the groups (effect estimate: -82.99ng.L-1; 95% CI -321.08 to 190.96; p=0.48). The incidence of MINS (p=0.063) and postoperative maximum troponin T (effect estimate: 0.45, 95% CI-1.66 to 3.41; p=0.728) concentrations within the first three postoperative days did not differ significantly between the groups. Conclusions: Levosimendan administration did not lead to a significantly lower release in postoperative NT-proBNP in cardiovascular risk patients undergoing major noncardiac surgery. There was no significant difference in MINS and postoperative Troponin T concentrations. The role of pre-emptive levosimendan as prophylactic treatment option in cardiovascular high-risk patients must be verified in large-scale trials.Keywords
All Related Versions
- Version 1, 2024-12-12, Research Square
- Published version: Nature Communications, 16 (1), 1.
This publication has 25 references indexed in Scilit:
- Perioperative supplemental oxygen and NT-proBNP concentrations after major abdominal surgery – A prospective randomized clinical trialJournal of Clinical Anesthesia, 2021
- Perioperative levosimendan in cardiac surgery: A systematic review with meta-analysis and trial sequential analysisInternational Journal of Cardiology, 2018
- Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary BypassJAMA, 2017
- Levosimendan for Hemodynamic Support after Cardiac SurgeryNew England Journal of Medicine, 2017
- Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac SurgeryJAMA, 2017
- Perioperative Major Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac SurgeryJAMA Cardiology, 2017
- Cardiac Complications in Patients Undergoing Major Noncardiac SurgeryNew England Journal of Medicine, 2015
- The Prognostic Value of Pre-Operative and Post-Operative B-Type Natriuretic Peptides in Patients Undergoing Noncardiac SurgeryJACC, 2014
- Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart FailureJACC: Heart Failure, 2013
- Duration of the Haemodynamic Action of a 24-h Infusion of Levosimendan in Patients with Congestive Heart FailureEuropean Journal of Heart Failure, 2007